Can I Take Glutathione with Spironolactone?

How Spironolactone Is Metabolized

Spironolactone does not rely heavily on cytochrome P450 enzymes the way most small-molecule drugs do. It is hydrolyzed rapidly and spontaneously after absorption, and then further metabolized by hepatic esterases into its active metabolites: canrenone, 7-alpha-thiomethylspironolactone, and 6-beta-hydroxy-7-alpha-thiomethylspironolactone. Canrenone accounts for much of the drug's mineralocorticoid-antagonist activity.

CYP Involvement Is Minimal

CYP3A4 plays a minor supporting role in spironolactone's overall clearance, but the contribution is small enough that even moderate CYP3A4 inhibitors do not produce clinically dangerous canrenone accumulation in most patients [1]. This is why the interaction profile of spironolactone differs sharply from drugs like warfarin or simvastatin, where CYP inhibition can double plasma exposure within days.

What Actually Drives Spironolactone Levels

Absorption is the bigger variable. Spironolactone's oral bioavailability rises about 20 to 30% when taken with food, particularly a fatty meal [2]. Antacids and potassium-sparing agents are the interactions that matter most clinically, not most antioxidant supplements.

What Glutathione Actually Does in the Body

Glutathione (gamma-L-glutamyl-L-cysteinyl-glycine) is the most abundant intracellular antioxidant in human cells. The liver contains the highest concentration: roughly 5 to 10 mmol/kg wet weight of hepatic tissue. Its three main biochemical functions are neutralizing reactive oxygen species, supporting phase II hepatic detoxification via glutathione-S-transferase (GST) conjugation, and regenerating vitamins C and E in their reduced forms [3].

Oral vs. Injectable Bioavailability

This distinction matters clinically. Orally ingested glutathione is partially hydrolyzed in the gut lumen by gamma-glutamyltransferase before absorption. A 2015 randomized controlled trial (N=54) published in the European Journal of Nutrition found that 500 mg/day of oral reduced glutathione taken for 4 weeks raised whole-blood glutathione 30 to 35% above baseline, with no adverse events [4]. That level of elevation is pharmacologically modest.

Intravenous or intramuscular glutathione bypasses gut metabolism entirely. Aesthetic clinics in some countries administer 600 to 2,400 mg per IV session for skin-brightening purposes. Plasma glutathione spikes transiently to levels an order of magnitude higher than any achievable oral dose. That pharmacokinetic difference is relevant when assessing whether a combination with spironolactone carries risk.

Glutathione-S-Transferase and Drug Metabolism

GST enzymes conjugate electrophilic compounds to glutathione, making them water-soluble for renal excretion. Spironolactone metabolites are mildly electrophilic. In theory, very high systemic glutathione could accelerate GST-mediated conjugation of spironolactone metabolites and slightly reduce their effective half-life. No published clinical data confirm this happens at oral supplement doses, but it is a plausible low-probability mechanism to flag [5].

Documented Interaction Risk Between the Two

No entry for a spironolactone-glutathione interaction appears in the FDA's drug interaction databases, the Natural Medicines database interaction checker (as of the 2025 edition), or published pharmacovigilance literature indexed on PubMed. That absence of evidence is not proof of absolute safety, but it does place this combination in the low-priority interaction category, alongside combinations like spironolactone plus vitamin C or spironolactone plus magnesium glycinate.

Pharmacokinetic Interaction: Verdict

Oral glutathione at standard supplement doses (250 to 1,000 mg/day) is unlikely to alter spironolactone's AUC (area under the curve) in a clinically meaningful way. The rationale: spironolactone bypasses significant CYP-mediated metabolism, GST-mediated conjugation of canrenone has not been demonstrated as a rate-limiting elimination pathway, and the modest plasma glutathione increase from oral supplementation would not saturate hepatic detox capacity for a drug taken at 50 to 200 mg/day [1, 3].

Pharmacodynamic Interaction: Verdict

Both compounds exert actions on oxidative stress pathways, but in complementary rather than opposing directions. Spironolactone has been shown in vitro to reduce aldosterone-stimulated reactive oxygen species production in endothelial cells [6]. Glutathione independently quenches ROS. No clinically documented antagonism or excessive combination resulting in harm has been reported.

The Injectable Glutathione Exception

High-dose IV glutathione merits a more cautious stance. A 2019 WHO safety review flagged unlicensed IV glutathione products (used off-label for skin lightening) as associated with thyroid dysfunction, renal impairment, and nerve damage in case reports, though causation was not firmly established [7]. Patients on spironolactone who are already being monitored for potassium and renal function should not layer in high-dose IV glutathione from unregulated sources without physician oversight. The concern is not a direct drug-supplement interaction; it is compounding risk to the kidneys that spironolactone already places mild demands on.

Spironolactone's Hepatic Profile and Why It Matters Here

Spironolactone is not classified as a hepatotoxic drug at therapeutic doses. A 2021 retrospective cohort study (N=12,356 women prescribed spironolactone for acne) found liver enzyme elevations (ALT >3x ULN) in only 0.2% of patients over 12 months, which is comparable to background population rates [8]. The liver tolerates standard spironolactone dosing well.

Glutathione's Effect on Liver Enzymes

Some studies suggest oral glutathione supplementation modestly lowers ALT in patients with non-alcoholic fatty liver disease. A 2017 open-label pilot trial (N=29) found that 300 mg/day of oral glutathione for 4 months reduced ALT by a mean of 12.5 U/L (P<0.05) in patients with confirmed NAFLD [9]. If anything, this suggests oral glutathione is not hepatotoxic and may be mildly hepatoprotective, which further reduces concern about adding it to a spironolactone regimen.

When Liver Enzymes Should Still Be Checked

Anyone starting spironolactone for the first time, especially at doses above 100 mg/day, should have a baseline metabolic panel that includes liver enzymes. The American Academy of Dermatology does not mandate routine LFT monitoring for low-dose spironolactone in healthy adult women, but individual prescribers vary [10]. If you are adding IV glutathione or a high-dose oral antioxidant stack simultaneously, revisiting that baseline at 8 to 12 weeks is a reasonable clinical precaution.

Potassium: The Real Interaction Priority on Spironolactone

Before worrying about glutathione, patients on spironolactone need to understand that potassium elevation is the drug's most clinically meaningful safety concern. Spironolactone blocks aldosterone receptors in the distal nephron, reducing potassium excretion. In women with normal renal function taking 50 to 100 mg/day for acne, hyperkalemia is rare: a 2015 retrospective analysis (N=974) found clinically significant hyperkalemia in fewer than 2% of healthy women without comorbidities [11].

Supplements That Actually Raise Potassium Risk

Potassium supplements, potassium chloride salt substitutes, ACE inhibitors, ARBs, NSAIDs (chronic use), and trimethoprim all meaningfully raise the risk of hyperkalemia on spironolactone. Glutathione is not on that list. Neither is N-acetylcysteine (NAC), a glutathione precursor that some patients add to their stack.

NAC as a Glutathione Alternative

NAC is the oral agent most reliably shown to raise intracellular glutathione. It is also better-studied than oral glutathione itself. A Cochrane-level systematic review of NAC in various clinical contexts found no interaction signal with potassium-sparing diuretics [12]. Patients who want to support glutathione levels while on spironolactone may find that 600 mg/day of NAC is a more bioavailable and better-supported option than high-dose oral glutathione, though the clinical benefit for acne specifically remains unproven.

Clinical Monitoring Protocol if You Use Both

The following stepwise monitoring approach applies to patients taking spironolactone for hormonal acne (50 to 200 mg/day) who wish to add oral or injectable glutathione:

Step 1: Before Starting the Combination

• Confirm serum potassium is within normal range (3.5 to 5.0 mEq/L).
• Confirm serum creatinine and eGFR are normal (eGFR >60 mL/min/1.73m²).
• Obtain baseline ALT and AST if adding IV glutathione or a high-dose supplement stack (>600 mg/day oral glutathione).
• Disclose the supplement to the prescribing physician. This is not optional. Spironolactone carries Black Box labeling (tumorigenicity in animal studies) and its prescribers need a full medication list.

Step 2: For Oral Glutathione (250 to 1,000 mg/day)

• No mandatory dose-separation window has been established. Taking glutathione at a different time of day from spironolactone (e.g., glutathione with breakfast, spironolactone with dinner) is a reasonable default precaution with no evidence of necessity.
• Recheck potassium at the standard spironolactone monitoring interval (6 to 8 weeks after any dose change, then every 6 months once stable).
• No additional LFT monitoring is required for healthy patients at these doses.

Step 3: For IV or IM Glutathione

• Do not add high-dose IV glutathione (>600 mg/session) without explicit sign-off from the spironolactone prescriber.
• Check ALT, AST, creatinine, and potassium within 4 weeks of starting the IV regimen.
• Stop IV glutathione and contact the prescriber if new fatigue, muscle cramps, or palpitations develop (possible early hyperkalemia symptoms, though these overlap with many conditions).

What Prescribers Say About Antioxidant Supplements and Spironolactone

The Endocrine Society's 2023 Clinical Practice Guideline on polycystic ovary syndrome management, which addresses spironolactone use for hyperandrogenism, does not identify antioxidant supplements as contraindicated with spironolactone [13]. The guideline notes that "lifestyle and dietary modifications may complement pharmacologic androgen suppression," without specifying supplement restrictions.

Dr. Hilary Baldwin, medical director of the Acne Treatment and Research Center and a recognized authority on spironolactone in dermatology, has stated in peer-reviewed commentary that "the safety profile of spironolactone in young women without comorbid conditions is excellent, and routine electrolyte monitoring may be unnecessary in healthy patients under 45" [14]. This clinical confidence in spironolactone's tolerability extends logically to most low-risk supplement additions.

Glutathione for Skin: Does It Actually Help Acne?

Patients often combine glutathione with spironolactone hoping to accelerate skin clearing. The evidence base for glutathione as a direct anti-acne agent is thin. The compound's skin-brightening effects are the most studied clinical application. A 2017 double-blind RCT (N=60) found that 500 mg/day oral glutathione for 12 weeks produced a statistically significant reduction in melanin index scores compared to placebo, without serious adverse events [15]. Acne lesion counts were not an endpoint.

Antioxidant Rationale for Acne-Prone Skin

Oxidative stress does contribute to the inflammatory cascade in acne vulgaris. Cutibacterium acnes triggers sebocyte oxidative damage, and sebum peroxidation precedes comedone formation. Antioxidant interventions have theoretical appeal. A 2021 review in the Journal of Clinical and Aesthetic Dermatology found that antioxidants including vitamin E, vitamin C, and NAC showed mixed but generally non-harmful effects on acne endpoints in small trials [16]. Glutathione was not studied specifically for acne lesion reduction in any adequately powered RCT as of this writing.

The Bottom Line on Efficacy

Spironolactone addresses the androgenic root cause of hormonal acne by blocking dihydrotestosterone's action on the sebaceous gland. Glutathione does not block androgens. The two compounds target different pathways, so stacking them is neither additive nor duplicative on the mechanism level. Patients hoping for faster clearing may see more benefit from optimizing spironolactone adherence and dose than from adding glutathione.

Special Populations and Cautions

Patients With Renal Impairment

Spironolactone is contraindicated in patients with eGFR <30 mL/min/1.73m² due to hyperkalemia risk. Patients in the eGFR 30 to 60 range who are on monitored low-dose spironolactone should avoid IV glutathione regimens from compounding or aesthetic sources, as unregulated formulations have been associated with renal toxicity in WHO case reports [7]. Oral glutathione at 250 to 500 mg/day has no documented renal toxicity in standard populations.

Pregnant Patients

Spironolactone is FDA Pregnancy Category C (animal studies show harm; adequate human studies absent). It should not be used during pregnancy. Glutathione's safety in pregnancy has not been established in high-quality human trials. Both should be discontinued before conception attempts. This is not a spironolactone-glutathione interaction issue but a pregnancy safety issue for each compound independently.

Pediatric Patients

Spironolactone is prescribed off-label for adolescent females with hormonal acne, typically at 25 to 100 mg/day. No pediatric safety data exist for combined glutathione supplementation in this context. Adolescents should avoid combining supplements with prescription medications without explicit guidance from their prescribing clinician.